Literature DB >> 28987955

The effects of dexmedetomidine preconditioning on aged rat heart of ischaemia reperfusion injury.

Jing Dong1, Xin Guo1, Shuhua Yang1, Lin Li2.   

Abstract

To assess the effect of dexmedetomidine on myocardial ischemia reperfusion injury in vivo aged rat heart. 40 healthy male, 20month aged, 350-400g Sprague-Dawley rats. Rats were divided into four groups randomly(n=10): group of ischemic preconditioning(IP group), group of Sham(CS group), group of dexmedetomidine(DP group), Ischemia-reperfusion injury group(IR group). The date of HR and ±dp/dtmax were detected before and after the occur of ischemia reperfusion. Superoxide dismutase (SOD) and malondialdehyde (MDA) activity were recorded; myocardial infarct size was calculated at the end of reperfusion. HR in each group decreased after thoracotomy. Compared with CS group, the HR in IR group reduced significantly (P<0.05). After given dexmedetomidine, HR in the DP group began to decrease significantly. Left heart function in IR group compared with the CS group showed that a statistically reduce of left ventricular function happened in IR group. ±dp/dtmax of the IR groups compared with the CS group were increased. SOD activity reduced and MDA in myocardial tissue homogenates increased in IR group (P<0.05); SOD activity in DP group compared with IR group deduced, MDA increased (P<0.05). Dexmedetomidine preconditioning can effectively reduce ischemia reperfusion injury of the aged rat in vivo, have a protective effect on aged rat heart.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Aged rat; Dexmedetomidine; Myocardial ischemia; Reperfusion injury

Mesh:

Substances:

Year:  2017        PMID: 28987955     DOI: 10.1016/j.rvsc.2017.09.028

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  7 in total

1.  Preconditioning in Ischemia-Reperfusion Lesion.

Authors:  Mariana Gatto; Gustavo Augusto Ferreira Mota; Luana Urbano Pagan; Mariana Janini Gomes; Marina Politi Okoshi
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.667

Review 2.  Ageing, sex, and cardioprotection.

Authors:  Marisol Ruiz-Meana; Kerstin Boengler; David Garcia-Dorado; Derek J Hausenloy; Tuuli Kaambre; Georgios Kararigas; Cinzia Perrino; Rainer Schulz; Kirsti Ytrehus
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

3.  Up-regulating microRNA-138-5p enhances the protective role of dexmedetomidine on myocardial ischemia-reperfusion injury mice via down-regulating Ltb4r1.

Authors:  Yanzi Chang; Lika Xing; Wenjuan Zhou; Wei Zhang
Journal:  Cell Cycle       Date:  2021-01-28       Impact factor: 4.534

4.  Dexmedetomidine Preconditioning Reduces Myocardial Ischemia-Reperfusion Injury in Rats by Inhibiting the PERK Pathway.

Authors:  YuJiao Chen; Song Cao; Hui Chen; CunZhi Yin; XinPeng Xu; ZaiQun Yang
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.000

Review 5.  Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.

Authors:  Meng Sun; Rong Wang; Rui Xia; Zhengyuan Xia; Zhilin Wu; Tingting Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

6.  Dexmedetomidine attenuates neuronal injury after spinal cord ischaemia-reperfusion injury by targeting the CNPY2-endoplasmic reticulum stress signalling.

Authors:  Lina Zhao; Meili Zhai; Xu Yang; Hongjie Guo; Ying Cao; Donghui Wang; Ping Li; Chong Liu
Journal:  J Cell Mol Med       Date:  2019-10-18       Impact factor: 5.310

7.  Dexmedetomidine improves cardiac function and protects against maladaptive remodeling following myocardial infarction.

Authors:  Hui Han; Daopeng Dai; Jinquan Hu; Jinzhou Zhu; Lin Lu; Guorong Tao; Ruiyan Zhang
Journal:  Mol Med Rep       Date:  2019-10-29       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.